Valneva SE (VALN)
NASDAQ: VALN · Real-Time Price · USD
10.27
-0.89 (-7.97%)
Aug 14, 2025, 11:33 AM - Market open
Valneva SE Revenue
Valneva SE had revenue of 48.33M EUR in the quarter ending June 30, 2025, with 26.98% growth. This brings the company's revenue in the last twelve months to 196.33M, up 25.47% year-over-year. In the year 2024, Valneva SE had annual revenue of 169.58M with 10.32% growth.
Revenue (ttm)
196.33M EUR
Revenue Growth
+25.47%
P/S Ratio
4.06
Revenue / Employee
275,353 EUR
Employees
713
Market Cap
936.39M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
VALN News
- 1 day ago - Valneva SE (VALN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Valneva Reports Half Year 2025 Financial Results and Provides Corporate Updates - GlobeNewsWire
- 7 days ago - Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ® in Elderly and Updates to the Prescribing Information - GlobeNewsWire
- 16 days ago - AGC Biologics' Heidelberg Site Supplies Drug Substance for Phase II Studies of Valneva's Tetravalent Shigella Vaccine Candidate - Business Wire
- 4 weeks ago - Valneva Announces Lifting of European Medicines Agency's Temporary Restriction on Use of Chikungunya Vaccine IXCHIQ® in Elderly - GlobeNewsWire
- 4 weeks ago - Europe lifts restriction on Valneva's chikungunya vaccine for elderly adults - Reuters
- 7 weeks ago - Valneva Announces Exclusive Vaccine Marketing and Distribution Agreement for Germany with CSL Seqirus - GlobeNewsWire
- 7 weeks ago - Valneva Announces Successful Outcome of its Annual General Meeting, Confirms FY 2025 guidance - GlobeNewsWire